(-0.12%) 5 462.91 points
(-0.10%) 39 074 points
(0.17%) 17 747 points
(-0.01%) $80.82
(-3.12%) $2.67
(-0.74%) $2 313.60
(0.23%) $28.94
(1.91%) $1 005.20
(0.32%) $0.936
(0.74%) $10.68
(0.51%) $0.792
(0.01%) $87.50
Live Chart Being Loaded With Signals
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company\'s pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia...
Stats | |
---|---|
आज की मात्रा | 31 931 |
औसत मात्रा | 35 256 |
बाजार मूल्य | 19.53M |
EPS | $-0.660 ( Q3 | 2023-11-06 ) |
Last Dividend | $1 801.73 ( 1980-05-12 ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.270 (7.58%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-26 | Devall Christopher Franklin | Buy | 7 000 | Common Stock |
2023-12-26 | Wool Kyle Michael | Buy | 5 000 | Common Stock |
2023-12-21 | Wool Kyle Michael | Buy | 630 050 | Common Stock |
2023-12-20 | Hayes Anthony | Buy | 70 000 | Common Stock |
2023-12-12 | Hayes Anthony | Buy | 2 000 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 98 transactions |
Buy: 6 932 818 | Sell: 0 |
मात्रा सहसंबंध
AIkido Pharma Inc. सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध | |
---|---|
GNACW | 0.901 |
10 सबसे अधिक नकारात्मक सहसंबंध | |
---|---|
DAOO | -0.958 |
GNAC | -0.946 |
IIII | -0.935 |
SHQA | -0.911 |
SCOA | -0.905 |
HCIC | -0.901 |
HCII | -0.894 |
HIIIU | -0.883 |
HCICU | -0.851 |
HIII | -0.847 |
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
AIkido Pharma Inc. सहसंबंध - मुद्रा/वस्त्र
AIkido Pharma Inc. वित्तीय
Annual | 2022 |
राजस्व: | $0 |
सकल लाभ: | $0 (0.00 %) |
EPS: | $-5.60 |
FY | 2022 |
राजस्व: | $0 |
सकल लाभ: | $0 (0.00 %) |
EPS: | $-5.60 |
FY | 2021 |
राजस्व: | $0.00 |
सकल लाभ: | $0.00 (0.00 %) |
EPS: | $-4.34 |
FY | 2020 |
राजस्व: | $0.00 |
सकल लाभ: | $0.00 (0.00 %) |
EPS: | $-7.47 |
Financial Reports:
No articles found.
AIkido Pharma Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $1 544.34 | 1978-05-15 |
Last Dividend | $1 801.73 | 1980-05-12 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | $5 147.79 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.53 | -- |
Div. Sustainability Score | 1.053 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
1978 | $0 | 0.00% |
1979 | $0 | 0.00% |
1980 | $0 | 0.00% |
1981 | $0 | 0.00% |
1982 | $0 | 0.00% |
1983 | $0 | 0.00% |
1984 | $0 | 0.00% |
1985 | $0 | 0.00% |
1986 | $0 | 0.00% |
1987 | $0 | 0.00% |
1988 | $0 | 0.00% |
1989 | $0 | 0.00% |
1990 | $0 | 0.00% |
1991 | $0 | 0.00% |
1992 | $0 | 0.00% |
1993 | $0 | 0.00% |
1994 | $0 | 0.00% |
1995 | $0 | 0.00% |
1996 | $0 | 0.00% |
1997 | $0 | 0.00% |
1998 | $0 | 0.00% |
1999 | $0 | 0.00% |
2000 | $0 | 0.00% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0 | 0.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
12 May 1980 | $1 801.73 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
14 May 1979 | $1 801.73 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
15 May 1978 | $1 544.34 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -19.43 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.318 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.306 | 1.500 | -4.51 | -6.76 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 20.26 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 16.48 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.55 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00650 | -1.500 | 9.89 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 36.16 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -3.04 | 2.00 | -1.012 | -2.02 | [0 - 30] |
freeCashFlowPerShareTTM | -3.10 | 2.00 | -1.552 | -3.10 | [0 - 20] |
debtEquityRatioTTM | 0.00704 | -1.500 | 9.97 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 1.000 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -23.01 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -39.50 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0164 | 0.800 | -3.22 | -2.58 | [0.5 - 2] |
Total Score | 1.053 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.947 | 1.000 | -0.197 | 0 | [1 - 100] |
returnOnEquityTTM | -0.306 | 2.50 | -2.90 | -6.76 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -3.10 | 2.00 | -1.035 | -3.10 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -3.04 | 2.00 | -1.012 | -2.02 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0144 | 1.500 | -3.43 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -15.70 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.67 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
AIkido Pharma Inc.
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company\'s pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं